EA2165

Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Contact phone
Nurse - Tracy 517-364-2835
Principal investigator
Gordan Srkalovic MD, PhD
Trial Category
Cancer
Trial SubCategory
Gastrointestinal